{
  "trial_id": "NCT02302716",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, ethnicity, body mass index (BMI), duration of type 2 diabetes mellitus, baseline HbA1c, baseline fasting plasma glucose, baseline insulin dose, use of oral antihyperglycemic medications, history of severe hypoglycemia, history of emergency room visits or hospitalizations due to poor glucose control, serum creatinine levels, liver function tests, history of cardiovascular disease, history of gastrointestinal disease, history of renal disease, history of cancer, history of HIV infection, pregnancy status, breastfeeding status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Baseline Hemoglobin A1c (HbA1c)",
          "baseline HbA1c"
        ],
        [
          "Duration of Diabetes",
          "duration of type 2 diabetes mellitus"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Sulfonylurea Group",
        "Time of basal insulin injection"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "body mass index (BMI)",
        "baseline fasting plasma glucose",
        "baseline insulin dose",
        "use of oral antihyperglycemic medications",
        "history of severe hypoglycemia",
        "history of emergency room visits or hospitalizations due to poor glucose control",
        "serum creatinine levels",
        "liver function tests",
        "history of cardiovascular disease",
        "history of gastrointestinal disease",
        "history of renal disease",
        "history of cancer",
        "history of HIV infection",
        "pregnancy status",
        "breastfeeding status"
      ]
    },
    "processed-gen-response": "Age, gender, race, ethnicity, body mass index (BMI), duration of type 2 diabetes mellitus, baseline HbA1c, baseline fasting plasma glucose, baseline insulin dose, use of oral antihyperglycemic medications, history of severe hypoglycemia, history of emergency room visits or hospitalizations due to poor glucose control, serum creatinine levels, liver function tests, history of cardiovascular disease, history of gastrointestinal disease, history of renal disease, history of cancer, history of HIV infection, pregnancy status, breastfeeding status."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Baseline HbA1c, Duration of Diabetes, Type of Oral Antihyperglycemic Medications, Basal Insulin Use, Systolic Blood Pressure, Diastolic Blood Pressure, Serum Creatinine, History of Severe Hypoglycemia, Number of Emergency Room Visits or Hospitalizations Due to Poor Glucose Control,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Baseline Hemoglobin A1c (HbA1c)",
          "Baseline HbA1c"
        ],
        [
          "Duration of Diabetes",
          "Duration of Diabetes"
        ]
      ],
      "remaining_reference_features": [
        "Sulfonylurea Group",
        "Time of basal insulin injection"
      ],
      "remaining_candidate_features": [
        "Body Mass Index",
        "Type of Oral Antihyperglycemic Medications",
        "Basal Insulin Use",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Serum Creatinine",
        "History of Severe Hypoglycemia",
        "Number of Emergency Room Visits or Hospitalizations Due to Poor Glucose Control"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, Baseline HbA1c, Duration of Diabetes, Type of Oral Antihyperglycemic Medications, Basal Insulin Use, Systolic Blood Pressure, Diastolic Blood Pressure, Serum Creatinine, History of Severe Hypoglycemia, Number of Emergency Room Visits or Hospitalizations Due to Poor Glucose Control"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Diabetes Diagnosis Duration, Body Mass Index, HbA1c, Systolic Blood Pressure, Diastolic Blood Pressure, Total Daily Dose of Insulin, Number of Oral Antihyperglycemic Medications, Duration of Type 2 Diabetes Mellitus.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Baseline Hemoglobin A1c (HbA1c)",
          "HbA1c"
        ],
        [
          "Duration of Diabetes",
          "Diabetes Diagnosis Duration"
        ]
      ],
      "remaining_reference_features": [
        "Race (NIH/OMB)",
        "Sulfonylurea Group",
        "Time of basal insulin injection"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Body Mass Index",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Total Daily Dose of Insulin",
        "Number of Oral Antihyperglycemic Medications",
        "Duration of Type 2 Diabetes Mellitus."
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Diabetes Diagnosis Duration, Body Mass Index, HbA1c, Systolic Blood Pressure, Diastolic Blood Pressure, Total Daily Dose of Insulin, Number of Oral Antihyperglycemic Medications, Duration of Type 2 Diabetes Mellitus."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of type 2 diabetes mellitus, HbA1c at baseline, fasting plasma glucose at baseline, systolic blood pressure, diastolic blood pressure, heart rate, smoking status, history of cardiovascular disease, history of hypertension, history of dyslipidemia, use of oral antihyperglycemic medications, use of basal insulin, total insulin dose at baseline.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Baseline Hemoglobin A1c (HbA1c)",
          "HbA1c at baseline"
        ],
        [
          "Duration of Diabetes",
          "duration of type 2 diabetes mellitus"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Sulfonylurea Group",
        "Time of basal insulin injection"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "body mass index (BMI)",
        "fasting plasma glucose at baseline",
        "systolic blood pressure",
        "diastolic blood pressure",
        "heart rate",
        "smoking status",
        "history of cardiovascular disease",
        "history of hypertension",
        "history of dyslipidemia",
        "use of oral antihyperglycemic medications",
        "use of basal insulin",
        "total insulin dose at baseline"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of type 2 diabetes mellitus, HbA1c at baseline, fasting plasma glucose at baseline, systolic blood pressure, diastolic blood pressure, heart rate, smoking status, history of cardiovascular disease, history of hypertension, history of dyslipidemia, use of oral antihyperglycemic medications, use of basal insulin, total insulin dose at baseline."
  }
}